Advances in CRISPR/Cas9 Technology for in Vivo Translation

Yagiz Anil Cicek, David C. Luther, Jessica A. Kretzmann, Vincent M. Rotello

Research output: Contribution to journalReview article

Abstract

Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized therapeutic gene editing by providing researchers with a new method to study and cure diseases previously considered untreatable. While the full range and power of CRISPR technology for therapeutics is being elucidated through in vitro studies, translation to in vivo studies is slow. To date there is no totally effective delivery strategy to carry CRISPR components to the target site in vivo. The complexity of in vivo delivery is furthered by the number of potential delivery methods, the different forms in which CRISPR can be delivered as a therapeutic, and the disease target and tissue type in question. There are major challenges and limitations to delivery strategies, and it is imperative that future directions are guided by well-conducted studies that consider the full effect these variables have on the eventual outcome. In this review we will discuss the advances of the latest in vivo CRISPR/Cas9 delivery strategies and highlight the challenges yet to be overcome.

Original languageEnglish
Pages (from-to)304-311
Number of pages8
JournalBiological and Pharmaceutical Bulletin
Volume42
Issue number3
DOIs
Publication statusPublished - Mar 2019

Cite this

Cicek, Y. A., Luther, D. C., Kretzmann, J. A., & Rotello, V. M. (2019). Advances in CRISPR/Cas9 Technology for in Vivo Translation. Biological and Pharmaceutical Bulletin, 42(3), 304-311. https://doi.org/10.1248/bpb.b18-00811
Cicek, Yagiz Anil ; Luther, David C. ; Kretzmann, Jessica A. ; Rotello, Vincent M. / Advances in CRISPR/Cas9 Technology for in Vivo Translation. In: Biological and Pharmaceutical Bulletin. 2019 ; Vol. 42, No. 3. pp. 304-311.
@article{1bb929d8fe924590a3726b6a9f536db7,
title = "Advances in CRISPR/Cas9 Technology for in Vivo Translation",
abstract = "Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized therapeutic gene editing by providing researchers with a new method to study and cure diseases previously considered untreatable. While the full range and power of CRISPR technology for therapeutics is being elucidated through in vitro studies, translation to in vivo studies is slow. To date there is no totally effective delivery strategy to carry CRISPR components to the target site in vivo. The complexity of in vivo delivery is furthered by the number of potential delivery methods, the different forms in which CRISPR can be delivered as a therapeutic, and the disease target and tissue type in question. There are major challenges and limitations to delivery strategies, and it is imperative that future directions are guided by well-conducted studies that consider the full effect these variables have on the eventual outcome. In this review we will discuss the advances of the latest in vivo CRISPR/Cas9 delivery strategies and highlight the challenges yet to be overcome.",
keywords = "clustered regularly interspaced short palindromic repeat, genomics, therapeutics, in vivo, HOMOLOGY-DIRECTED-REPAIR, MOUSE MODEL, MESSENGER-RNA, GENE DELIVERY, ADENOASSOCIATED VIRUS, NANOPARTICLE DELIVERY, NONVIRAL VECTORS, GENOME, ADENOVIRUS, CAS9",
author = "Cicek, {Yagiz Anil} and Luther, {David C.} and Kretzmann, {Jessica A.} and Rotello, {Vincent M.}",
year = "2019",
month = "3",
doi = "10.1248/bpb.b18-00811",
language = "English",
volume = "42",
pages = "304--311",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "PHARMACEUTICAL SOC JAPAN",
number = "3",

}

Cicek, YA, Luther, DC, Kretzmann, JA & Rotello, VM 2019, 'Advances in CRISPR/Cas9 Technology for in Vivo Translation' Biological and Pharmaceutical Bulletin, vol. 42, no. 3, pp. 304-311. https://doi.org/10.1248/bpb.b18-00811

Advances in CRISPR/Cas9 Technology for in Vivo Translation. / Cicek, Yagiz Anil; Luther, David C.; Kretzmann, Jessica A.; Rotello, Vincent M.

In: Biological and Pharmaceutical Bulletin, Vol. 42, No. 3, 03.2019, p. 304-311.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advances in CRISPR/Cas9 Technology for in Vivo Translation

AU - Cicek, Yagiz Anil

AU - Luther, David C.

AU - Kretzmann, Jessica A.

AU - Rotello, Vincent M.

PY - 2019/3

Y1 - 2019/3

N2 - Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized therapeutic gene editing by providing researchers with a new method to study and cure diseases previously considered untreatable. While the full range and power of CRISPR technology for therapeutics is being elucidated through in vitro studies, translation to in vivo studies is slow. To date there is no totally effective delivery strategy to carry CRISPR components to the target site in vivo. The complexity of in vivo delivery is furthered by the number of potential delivery methods, the different forms in which CRISPR can be delivered as a therapeutic, and the disease target and tissue type in question. There are major challenges and limitations to delivery strategies, and it is imperative that future directions are guided by well-conducted studies that consider the full effect these variables have on the eventual outcome. In this review we will discuss the advances of the latest in vivo CRISPR/Cas9 delivery strategies and highlight the challenges yet to be overcome.

AB - Clustered regularly interspaced short palindromic repeats(CRISPR)/CRISPR-associated protein 9 (Cas9) technology has revolutionized therapeutic gene editing by providing researchers with a new method to study and cure diseases previously considered untreatable. While the full range and power of CRISPR technology for therapeutics is being elucidated through in vitro studies, translation to in vivo studies is slow. To date there is no totally effective delivery strategy to carry CRISPR components to the target site in vivo. The complexity of in vivo delivery is furthered by the number of potential delivery methods, the different forms in which CRISPR can be delivered as a therapeutic, and the disease target and tissue type in question. There are major challenges and limitations to delivery strategies, and it is imperative that future directions are guided by well-conducted studies that consider the full effect these variables have on the eventual outcome. In this review we will discuss the advances of the latest in vivo CRISPR/Cas9 delivery strategies and highlight the challenges yet to be overcome.

KW - clustered regularly interspaced short palindromic repeat

KW - genomics

KW - therapeutics

KW - in vivo

KW - HOMOLOGY-DIRECTED-REPAIR

KW - MOUSE MODEL

KW - MESSENGER-RNA

KW - GENE DELIVERY

KW - ADENOASSOCIATED VIRUS

KW - NANOPARTICLE DELIVERY

KW - NONVIRAL VECTORS

KW - GENOME

KW - ADENOVIRUS

KW - CAS9

U2 - 10.1248/bpb.b18-00811

DO - 10.1248/bpb.b18-00811

M3 - Review article

VL - 42

SP - 304

EP - 311

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 3

ER -